Skip to content

The effective dose and NT50 of ciprofol for general anesthesia induction in adult patients of different ages were determined by sequential method

The effective dose and NT50 of ciprofol for general anesthesia induction in adult patients of different ages were determined by sequential method

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072307
Enrollment
Unknown
Registered
2023-06-09
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Application of general anesthesia

Interventions

Youth group (18~40 years old):According to the success of sedation induced by general anesthesia, the sequential method was used to increase or decrease the induced dose of ciprofol
Middle-aged group (41~65 years old):According to the success of sedation induced by general anesthesia, the sequential method was used to increase or decrease the induced dose of ciprofol
Elderly group (66 ~ 85 years old):According to the success of sedation induced by general anesthesia, the sequential method was used to increase or decrease the induced dose of ciprofol

Sponsors

Boai Hospital of Zhongshan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Age range from 18 to 85 years old, gender is not limited; 2) Patients undergoing elective tracheal intubation general anesthesia; 3) BMI 18.5 ~ 24.9kg/m2; 4) ASA ? or ? level; 5) Normal head and neck motion, Mallampati ? or ?.

Exclusion criteria

Exclusion criteria: 1) Patients who refuse to participate or are not suitable to participate in this trial; 2) Emergency surgery; 3) Patients with hypovolemia and shock; 4) History of general anesthesia or use of other sedative drugs within 1 month; 5) Allergic to ciprofol , non-depolarizing muscle relaxants, and opioids; 6) Neuromuscular junction disease myasthenia gravis, schizophrenia, severe depression, etc.; 7) Patients with cardiovascular diseases and serious functional impairment of liver, kidney, lung and other important organs; 8) Severe anemia, coagulation dysfunction, etc.; 9) Difficulty in managing respiratory tract; 10) A history of drug and/or alcohol abuse.

Design outcomes

Primary

MeasureTime frame
MOAA/S score;

Secondary

MeasureTime frame
Narctored value;MAP, HR, SPO2;Injection pain score;Adverse reactions of perioperative patients;

Countries

China

Contacts

Public ContactLizhen Deng

Boai Hospital of Zhongshan,Southern

denglz2013@163.com+86 159 7606 1066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026